KIT and gastrointestinal stromal tumor: The importance of conventional cytotoxic chemotherapy is underlined in adjuvant treatments, where only trastuzumab and imatinib are currently approved in HER2- (human epidermal growth factor receptor 2-) positive early breast cancer and Kit-positive gastrointestinal stromal tumour (GIST) treatments, respectively.